Comparing cisplatin plus etoposide with combination of mitomycin, ifosfamide and cisplatin in advanced non-small cell lung cancer patients;İleri evre küçük hücreli dişi akciǧer karsinomunda sisplatin-etoposid ile mitomisin-ifosfamid-sisplatin kombinasyonlarinin karşilaştirilmasi

Tuberkuloz ve Toraks

Volumn 54, Issue 2, 2006, Pages 161-167

  Çok, Gürsel ^a   Göksel, Tuncay ^a   Soyer, Serdar ^a   Atil, Hülya ^a   Güzelant, Asuman ^a   Aysan, Tülin ^a  

^a EGE UNIVERSITY   (Turkey)

Author keywords

Cisplatin; Etoposide; Ifosfamide; Mitomycin; Non small cell lung cancer

Indexed keywords

CISPLATIN; ETOPOSIDE; IFOSFAMIDE; MITOMYCIN; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHI SQUARE TEST; COMPUTER PROGRAM; CONTROLLED STUDY; FEMALE; GRANULOCYTOPENIA; HUMAN; KAPLAN MEIER METHOD; LEUKOPENIA; LOGISTIC REGRESSION ANALYSIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PROPORTIONAL HAZARDS MODEL; STATISTICAL ANALYSIS; STUDENT T TEST; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; COMPARATIVE STUDY; EVALUATION; LUNG TUMOR; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME; TURKEY (REPUBLIC);

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; ETOPOSIDE; FEMALE; HUMANS; IFOSFAMIDE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TURKEY;

EID: 33747062672     PISSN: 04941373     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Crino L, Clerici M, Figoli F, et al. Superiority of three-drug combination chemotherapy versus cisplatin-etoposide in advanced non-small cell lung cancer: A randomized trial by the Italian Oncology Group for Clinical research. Lung Cancer 1995; 12: 125-32.
2. Dillman RO, Seagren SL, Properl KJ, et al. A randomized trial of induction chemotherapy plus high dose radiation versus radiatione alone in stage III non-small cell lung cancer. N Engl J Med 1990; 232: 940-5.
3. Kubota K, Furuse K, Kawahara M, et al. Role of radiotherapy in combined modality treatment of locally advanced non-small-cell lung cancer. J Clin Oncol 1994; 12: 1547-52.
4. Kubota K, Furuse K, Kawahara M, et al. Cisplatin-based combination chemotherapy for elderly patients with non-small-cell lung cancer. Cancer Chemother Pharmacol 1997; 40: 469-74.
5. Martini N, Kris MG, Flehinger BJ, et al. Preoperative chemotherapy for stage III A(N2) lung cancer: The Sloan-Kettering experience with 136 patients. Ann Thorac Surg 1993; 55: 1365-74.
6. Bunn PA. The expanding role of cisplatin in the treatment of non-small cell lung cancer. Sem Oncol 1989; 16: 10-21.
7. Crin L, Tonato M, Darwish S, et al. A randomized trial of three cisplatin containing regimens in advanced non-small cell lung cancer: A study of the Umbria Group. Cancer Chemoter Pharmacol 1990; 26: 52-6.
8. Kris MG, Gralla RJ, Kalman L, et al. Randomised trial comparing vindesine plus cisplatin with vinblastine plus ciplatin in patients with non-small cell lung cancer, with an analysis of methods of response assessment. Cancer Treat Rep 1985; 69: 387-95.
9. Gandara DR, Crowley C, Livingstone RB, et al. Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: A phase III study of the Southwest Oncology Group. J Clin Oncol 2001; 6: 80-6.
10. Urban T, Bedin A, Baud M, et al. Efficacy and toxicity of mitomycin, ifosfamide, and cisplatin (MIP) in patients with inoperable non-small cell lung cancer. Lung Cancer 1996; 14: 109-17.
11. Polyzos A, Tsavaris H, Veslemes M, et al. Chemotherapy of non-small cell lung cancer. A prospectively randomized study of cisplatin-etoposide versus cisplatin-mitomycin-vinbtastine. J Chemother 1997; 9: 102-5.
12. Soh LT, Tan EH, Ang PT. Mitomycin, ifosfamide and cisplatin in advanced non-small cell lung cancer. Singapore Med J 1998; 39: 357-8.
13. Palmer AJ, Brandt A. The cost-effectiveness of four cisplatin- containing chemotherapy regimens in the treatment of stages IIIB and IV non-small cell lung cancer: An Italian perspective. Monaldi Arch Chest Dis 1996; 51: 279-88.